Once more than 4 percent of tau molecules in a person’s blood are phosphorylated at residue 217, the clock starts ticking—toward the first symptoms of Alzheimer’s disease, that is. How long it might ...
Post-marketing data chart immunotherapy performance in early-onset Alzheimer’s. The antibodies lowered amyloid and slowed functional decline. However, tangles continued to form. “These results offer ...
If a person with no cognitive complaints tests positive for brain amyloid based on plasma p-tau217, what should their doctor tell them about their likelihood of getting Alzheimer’s disease? That’s the ...
On November 24, Novo Nordisk announced that the GLP-1 mimetic semaglutide had failed to slow progression of Alzheimer’s disease in two Phase 3 trials. Even though the cat was out of the bag, ...
Transferrin-receptor shuttles distribute antibody cargo throughout the parenchyma, steering clear of ARIA-provoking vascular amyloid. Trontinemab is enrolling Phase 3 for early AD, announces plans for ...
Bifidobacterium breve A1 is a proprietary strain of probiotic bacteria isolated from the intestinal tract of an infant. A main component of the human gut microbiome, Bifidobacteria species form part ...
As the trained killers of the immune system, cytotoxic T cells silently save our lives every day—vanquishing viruses before they can run amok, and putting nascent cancer cells out of business before ...
Talk about a closely watched study. Conference after conference, Roche scientists running the ongoing Brain Shuttle AD trial of trontinemab are dispensing morsels of news from sequential interim ...
As advanced biomedical technologies have allowed scientists to gather growing and increasingly complex datasets, even the most brilliant human minds grappling with the windfall can’t possibly keep up.
At the 19th AD/PD conference, Alzforum reporters wrote 15 summaries of findings across both diseases. From a step toward finally having an α-synuclein PET tracer to a major focus on Trem2 as a drug ...
As the baby boom generation reaches its hopefully golden years, scientists have been projecting a doubling of dementia cases in the U.S. by 2050, alarming health care agencies, the public, and health ...
The fifth time may be the charm for antibodies targeting tau. At the 16th Clinical Trials on Alzheimer’s Disease conference, held October 29 to November 1 in Madrid, Brussels-based UCB Pharma ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results